

Dr Philip Mease is Director of Rheumatology Research at the Swedish Medical Center and Providence St Joseph Health and Clinical Professor at the University of Washington School of Medicine, Seattle, WA. His clinical practice is based at Seattle Rheumatology Associates. Dr Mease earned his undergraduate and medical degrees at Stanford University, Stanford, CA and completed his residency in internal medicine and fellowship in rheumatology at the University of Washington School of Medicine.

Dr Mease's research interests include psoriatic arthritis (PsA), spondyloarthritis (SpA), rheumatoid arthritis (RA), osteoarthritis (OA), fibromyalgia (FM) and systemic lupus erythematosus (SLE), focusing on disease state, outcome measurement and efficacy and safety of emerging therapies for these conditions. He has authored over 650 journal articles, over a thousand abstracts, and edited textbooks on PsA and axial SpA. His seminal 2000 Lancet paper established the efficacy of anti-TNF therapy in PsA. Expertscape ranks Professor Mease as the most published expert in PsA and psoriasis in the last 10 years, and the 12th most published in spondyloarthritis. He is ranked in the top 40 most cited University of Washington faculty. He is a reviewer for multiple leading rheumatology journals as well as the *New England Journal of*

Medicine and Lancet. He has received a lifetime achievement award from the National Psoriasis Foundation and the Arthritis Foundation. He is a Master of the American College of Rheumatology and has received its Medical Communicator award for education.

Dr Mease is a past president and founding organizer of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and is a member of the Assessment of Spondyloarthritis International Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). He has also been active in the Outcome Measures in Rheumatology (OMERACT) research organization as co-chair of the PsA and chronic pain working groups and as a member of the steering committee. He is the scientific director of the CorEvitas US national PsA/SpA registry, and is the autoimmune disease consultant for Artificial Intelligence (AI) population research in the Providence Health system data base through the Institute of Systems Biology in Seattle.